FGFR is the fibroblast growth factor receptor (Fibroblast Growth Factor Receptor). The FGFR family mainly includes four subtypes, FGFR1, FGFR2, FGFR3 and FGFR4. It is part of the tyrosine kinase signaling pathway responsible for cell proliferation and differentiation. There are currently several FGFR inhibitors in clinical trials or approval stages, among which Pemigatinib and Infigratinib have been approved by the US Food and Drug Administration (FDA). Pemigatinib is a selective competitive inhibitor of FGFR1, FGFR2 and FGFR3, the treatment response rate for patients with locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or rearrangement is as high as 35.5%. Therefore, detection of FGFR1/2/3 fusion genes in patients with cholangiocarcinoma to guide targeted therapy can further improve the survival of patients .

The detection of FGFR gene in patients with cholangiocarcinoma, to select appropriate targeted drugs for the patients based on the gene variation information, so as to improve the pertinence and effectiveness of treatment, realize individualized treatment.

Patients with cholangiocarcinoma.

1.Nucleic Acid Extraction

2.Library Preparation （3.5 hours total time）

3.Sequencing

4.Auto-data Analysis

5.Report